Roche scru­ti­nized by UK watch­dog over 'mis­lead­ing' Ro­z­lytrek pro­mo­tion­al web­site

The UK’s Pre­scrip­tion Med­i­cines Code of Prac­tice Au­thor­i­ty (PM­C­PA) has ruled that a Roche web­page for its can­cer med­ica­tion Ro­z­lytrek mis­led health­care pro­fes­sion­als.

The al­le­ga­tions stemmed from an anony­mous com­plaint filed by a self-pro­claimed health pro­fes­sion­al who ar­gued that Roche’s re­sources web­site left out im­por­tant in­for­ma­tion around po­ten­tial dose re­duc­tions and dis­con­tin­u­a­tions for cer­tain pa­tients be­ing mon­i­tored on the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER